Professor Kausik Ray, BSc(Hons), MBChB, MD, MPhil (Cantab), FRCP (Lon), FRCP (Ed), FACC, FESC, FAHA

Kausik Ray is a Professor of Public Health at the School of Public Health, the Director of the Imperial Centre for Cardiovascular Disease Prevention and the Deputy Director of the Imperial Clinical Trial Unit, Imperial College London, and a Consultant Cardiologist.

Contributions

Panel Discussion: FHSC-Implementing Global Screening Strategies for FH91th EAS Congress 2023FHSC-Implementing Global Screening Strategies for FHWhat have we learnt about Peadiatric Screening from the FHSC91th EAS Congress 2023FHSC-Implementing Global Screening Strategies for FHFH WeekEstimating the potential impact of LDL-C lowering through siRNA therapies on population health: a simulation study91th EAS Congress 2023Late Breaker - ClinicalLipid management in patients with high and very high cardiovascular risk: data from routine clinical practice in europe (SANTORINI study)91th EAS Congress 2023Late Breaker - ClinicalPanel Discussion: EAS/NLA joint symposium - Registry updates91th EAS Congress 2023EAS/NLA joint symposium - Registry updatesThe SANTORINI and HEYMANS registries91th EAS Congress 2023EAS/NLA joint symposium - Registry updatesPanel Discussion: IAS/EAS joint session - Cardiometabolic traits - The next battleground in Atherosclerosis91th EAS Congress 2023IAS/EAS joint session - Cardiometabolic traits - The next battleground in AtherosclerosisPanel Discussion: WHF Cholesterol Roadmap - Cholesterol Lowering Throughout the Life-course91th EAS Congress 2023WHF Cholesterol Roadmap- Cholesterol Lowering Throughout the Life-courseThe 8 Pillars of Cholesterol Lowering throughout the Life-course91th EAS Congress 2023WHF Cholesterol Roadmap- Cholesterol Lowering Throughout the Life-coursePanel Discussion: Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?91th EAS Congress 2023FIBRATES The PROMINENT trial91th EAS Congress 2023Elevated triglycerides and reduction of CV risk: What did we learn after REDUCE-IT?Panel Discussion: Re-thinking Lipid Management in Patients with High and Very High Cardiovascular RiskRe-thinking Lipid Management in Patients with High and Very High Cardiovascular Risk91th EAS Congress 2023Lipid management in Europe the SANTORINI study91th EAS Congress 2023Re-thinking Lipid Management in Patients with High and Very High Cardiovascular RiskLCN Lp(a) webinar series #5: Round table with the experts – How to use L(a) in practice, from the point of view of the cardiologist, the lipidologist, the diabetologist and the patientWebinars on-demandNLA/EAS joint session - Primordial prevention: The neglected topic - Discussion and Q&ANLA/EAS joint session - Primordial prevention: The neglected topic90th EAS Congress 2022WHF Session 2: Global FH - Panel discussionFH Week90th EAS Congress 2022WHF Session 2: Global FH(DyslipidemiaMonogenicFHheLipidologyHypercholesterolemiaPrimary HyperlipidemiaReview)Why and how to implement early combination lipid lowering therapy - Discussion and Q&A90th EAS Congress 2022Why and how to implement early combination lipid lowering therapyAn App to guide clinical care - what is it and how should we use it90th EAS Congress 2022Why and how to implement early combination lipid lowering therapyObicetrapib lowers LDL-C in patients on high intensity statins results from the rose trial (nct04753606)90th EAS Congress 2022Late breaker session 1WHF Session 1: WHF Roadmap on Cholesterol update - Discussion and Q&A90th EAS Congress 2022WHF Session 1: WHF Roadmap on Cholesterol updateOverall Concept90th EAS Congress 2022WHF Session 1: WHF Roadmap on Cholesterol updateReimagining population health-the time is now - Discussion and Q&AReimagining population health-the time is now90th EAS Congress 2022Reimagining prevention: the population approachReimagining population health-the time is now90th EAS Congress 2022Implementation of the 2019 lipid guidelines-where are we now? - Discussion and Q&A90th EAS Congress 2022Implementation of the 2019 lipid guidelines-where are we now?What’s been achieved and what more is needed - real world evidence90th EAS Congress 2022Implementation of the 2019 lipid guidelines-where are we now?Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD Prevention - Discussion and Q&A90th EAS Congress 2022Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD PreventionThe epidemiology of DM and obesity and risk of ASCVD90th EAS Congress 2022Diabetes, Obesity and Atherosclerosis - New Horizons in ASCVD PreventionThe role of new lipid lowering drugsEAS AC on FHThe population burden of FH- The need to close the gapEAS AC on FHHDL, non HDL cholesterol and TG - a role in atherosclerosis?EAS AC in LipidologyFamilial hypercholesterolemia detection and treatment and the EAS InitiativesEAS AC in LipidologyWhat do we know so far about bempedoic acid?88th EAS Congress 2020siRNA based approaches targeting hepatic synthesis of PCSK988th EAS Congress 2020Risk Prediction for Add on Lipid Modulating Therapy87th EAS Congress 2019Why TG-rich lipoproteins-non-HDL-Cholesterol matter when assessing CVD risk? - Introduction85th EAS Congress 2017Familial hypercholesterolaemia85th EAS Congress 2017Cardiovascular risk assessment and lipid lowering for patients with DM - what do the guidelines say?2019 ESC-EAS Dyslipidaemia Guidelines